116 related articles for article (PubMed ID: 11989593)
1. Mitomycin C and vinblastine in anthracycline-resistant metastatic breast cancer: a phase II study.
Kalofonos HP; Onyenadum A; Kosmas C; Koutras A; Petsas T; Efthimiou V; Koukouras D; Tzoracolefterakis E; Andrikopoulos P; Androulakis J
Tumori; 2001; 87(6):394-7. PubMed ID: 11989593
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin C and vinblastine in combination with amifostine in metastatic breast cancer. A feasibility study of the EORTC--Investigational Drug Branch for Breast Cancer (IDBBC).
Kusenda Z; Kerger J; Awada A; Geurs F; Van Vreckem A; Habboubi N; Piccart MJ
Support Care Cancer; 1997 Sep; 5(5):414-6. PubMed ID: 9322355
[TBL] [Abstract][Full Text] [Related]
4. Effective treatment of advanced breast cancer with vinorelbine, mitomycin C plus human granulocyte colony-stimulating factor.
Kornek GV; Haider K; Kwasny W; Hejna M; Raderer M; Meghdadi S; Burger D; Schneeweiss B; Depisch D; Scheithauer W
Br J Cancer; 1996 Nov; 74(10):1668-73. PubMed ID: 8932353
[TBL] [Abstract][Full Text] [Related]
5. Mitomycin C and vinblastine: an active regimen in previously treated breast cancer patients.
Ospovat I; Siegelmann-Danieli N; Grenader T; Hubert A; Hamburger T; Peretz T
Tumori; 2009; 95(6):683-6. PubMed ID: 20210229
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea did not enhance the clinical response to vinblastine in patients with anthracycline-resistant metastatic breast cancer.
Huan SD; Yau JC; Tomiak E; Goel R; Cripps C; Gertler SZ; Prosser IA; Stewart DJ
Tumori; 1996; 82(6):576-8. PubMed ID: 9061067
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
8. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
10. Mitomycin C and vinorelbine in pretreated breast cancer.
Colleoni M; Manente P; Stocker J; Amor H; Lamon S; Nelli P; Vicario G; Sgarbossa G; Graiff C
Tumori; 1997; 83(5):834-6. PubMed ID: 9428918
[TBL] [Abstract][Full Text] [Related]
11. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
[TBL] [Abstract][Full Text] [Related]
12. Vinorelbine and cisplatin in metastatic breast cancer patients previously treated with anthracyclines.
Vassilomanolakis M; Koumakis G; Barbounis V; Demiri M; Pateras H; Efremidis AP
Ann Oncol; 2000 Sep; 11(9):1155-60. PubMed ID: 11061611
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of paclitaxel/cisplatin combination in patients with metastatic breast cancer refractory to anthracycline-based chemotherapy.
Rosati G; Riccardi F; Tucci A; De Rosa P; Pacilio G
Tumori; 2000; 86(3):207-10. PubMed ID: 10939600
[TBL] [Abstract][Full Text] [Related]
14. Mitomycin "C" and vinorelbine as second line chemotherapy for metastatic breast carcinoma.
Agostara B; Gebbia V; Testa A; Cusimano MP; Gebbia N; Callari AM
Tumori; 1994 Feb; 80(1):33-6. PubMed ID: 8191595
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure.
Martín M; Lluch A; Casado A; Garciía Carbonero I; de Paz L; Esteban C; Insa A; Alfonso R; García-Conde J; Diaz-Rubio E
Ann Oncol; 2000 Jan; 11(1):85-9. PubMed ID: 10690393
[TBL] [Abstract][Full Text] [Related]
16. Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer.
Havlin KA; Ramirez MJ; Legler CM; Harris LN; Matulonis UA; Hohneker JA; Hayes DF; Winer EP
Cancer Chemother Pharmacol; 1999; 43(1):68-72. PubMed ID: 9923543
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
[TBL] [Abstract][Full Text] [Related]
19. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of mitomycin C, 5'-deoxy-5-fluorouridine, etoposide and medroxyprogesterone acetate (McVD-MPA) as a salvage chemotherapy to anthracycline-resistant tumor in relapsed breast cancer and its mechanism(s) of antitumor action.
Kim R; Osaki A; Tanabe K; Kojima J; Toge T
Oncol Rep; 2001; 8(3):597-603. PubMed ID: 11295087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
